AtaiBeckley (ATAI) Depreciation & Amortization (CF) (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Depreciation & Amortization (CF) came in at $233000.0 in Q3 2025, up 180.72% year-on-year from $83000.0 in Q3 2024, and up 2.64% quarter-over-quarter from $227000.0 in Q2 2025.
AtaiBeckley (ATAI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
AtaiBeckley's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $167000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 22.69% year-over-year to $167000.0; the TTM figure through Mar 2026 stood at $383000.0 (changed N/A YoY), while the FY2025 annual figure was $1.0 million, up 113.95% from the prior year.
- Depreciation & Amortization (CF) came in at $233000.0 for Q3 2025 at AtaiBeckley, up from $227000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $216000.0 in Q1 2025 to a low of $167000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $74000.0 (2023), against an average of $88578.9.
- Across the five-year window, Depreciation & Amortization (CF) plunged 240.0% in 2021 and surged 900.0% in 2022, its largest moves.
- AtaiBeckley's Depreciation & Amortization (CF) stood at $29000.0 in 2021, then soared by 82.76% to $53000.0 in 2022, then soared by 90.57% to $101000.0 in 2023, then surged by 122.77% to $225000.0 in 2024, then advanced by 3.56% to $233000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $233000.0 (Q3 2025), $227000.0 (Q2 2025), and $216000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | 167,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 167,000.00 |
| Mar 31, 2026 | 167,000.00 |
| Sep 30, 2025 | 233,000.00 |
| Sep 30, 2025 | 233,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Dec 31, 2024 | 225,000.00 |
| Dec 31, 2024 | 225,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Dec 31, 2023 | 101,000.00 |